Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

Annals of Neurology

Volumn 46, Issue 3, 1999, Pages 419-424

  Kordower, Jeffrey H ^a   Palfi, Stephane ^a   Chen, Er Yun ^a   Ma, Shuang Y ^a   Sendera, Timothy ^a   Cochran, Elizabeth J ^a   Mufson, Elliott J ^a   Penn, Richard ^a   Goetz, Christopher G ^a   Comella, Cynthia D ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; NEURITE PROMOTING FACTOR;

AGED; ANOREXIA; ARTICLE; AUTOPSY; CASE REPORT; CLINICAL TRIAL; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERANCE; HALLUCINATION; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; MORTALITY; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SKIN TINGLING; TREATMENT OUTCOME;

AGED; BRAIN; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; IMMUNOENZYME TECHNIQUES; INJECTIONS, INTRAVENTRICULAR; MALE; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 0032850453     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q     Document Type: Article

References (15)

1. Lapchak PA, Gash DM, Collins F, et al. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): Preclinical development and application to the treatment of Parkinson's disease. Exp Neurol 1997;145:309-321
2. Kordower JH, Rosenstein JM, Collier TJ, et al. Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 1995;370:203-230
3. Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: Immunochemical characterization and localization in brain. J Neurosci 1995;15:1714-1723
4. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:1118-1124
5. Fearnly J, Lees A. Pathology of Parkinson's disease. In: Calne D, ed. Neurodegenerative diseases. Philadelphia: WB Saunders, 1994:545-554
6. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880
7. Kojima H, Abiru Y, Sakajiri K, et al. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain. Biochem Biophys Res Commun 1997;238:569-573
8. Björklund A, Rosenblad C, Winkler C, et al. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 1997;4: 186-200
9. Choi-Lundberg DL, Lin Q, Chang YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997;275:838-841
10. Mandel RJ, Spratt SK, Snyder RO, et al. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 1997;94: 14083-14088
11. Lindner MD, Winn SR, Baetge EE, et al. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp Neurol 1995;132:62-76
12. Emerich DF, Plone M, Francis MJ, et al. Alleviation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts. Brain Res 1996;736: 99-110
13. Choi-Lundberg DL, Lin Q, Schallert T, et al. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol 1998;154:261-276
14. Bilang-Bleuel AF, Revah P, Colin I, et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 1997;94:8818-8823
15. Sautter J, Tseng JL, Braguglia D, et al. Implants of polymerencapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp Neurol 1998;149: 230-236